scholarly journals Rethinking Risk for Pneumococcal Disease in Adults: The Role of Risk Stacking

2015 ◽  
Vol 2 (1) ◽  
Author(s):  
Stephen I. Pelton ◽  
Kimberly M. Shea ◽  
Derek Weycker ◽  
Raymond A. Farkouh ◽  
David R. Strutton ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
High Risk ◽  
Pneumococcal Disease ◽  
Disease Incidence ◽  
Neuromuscular Disorder ◽  
Incidence Rates ◽  
Comorbid Conditions ◽  
Private Healthcare ◽  
Using Data

Abstract Using data from 3 private healthcare claims repositories, we evaluated the incidence of pneumococcal disease among adults with US Advisory Committee on Immunization Practices (ACIP) defined at-risk conditions or rheumatoid arthritis, lupus, Crohn's disease, and neuromuscular disorder/seizures and those with traditional high-risk conditions. We observed that adults with ≥2 concurrent comorbid conditions had pneumococcal disease incidence rates that were as high as or higher than rates observed in those with traditional high-risk conditions.

The Role of Manual Occupation in the Aetiology of Dupuytren’s Disease in Men in England and Wales

2004 ◽  
Vol 29 (1) ◽  
pp. 12-14 ◽  
Author(s):  
A. A. KHAN ◽  
O. J. RIDER ◽  
C. U. JAYADEV ◽  
C. HERAS-PALOU ◽  
H. GIELE ◽  
...  
Keyword(s):  
The Elderly ◽  
Incidence Rates ◽  
Social Classes ◽  
Dupuytren’S Disease ◽  
Dupuytren's Disease ◽  
England And Wales ◽  
Occupational Social Class ◽  
Using Data ◽  
Manual Occupation

We compared the incidence of significant Dupuytren’s disease in men across occupational social classes in England and Wales, using data from the National Morbidity Survey. We found that manual occupational social class was not associated with an increased incidence of Dupuytren’s disease. In fact, the incidence rates of Dupuytren’s disease in the elderly were higher in non-manual than in manual social classes.

Incidence of New-onset and Flare of Preexisting Psoriasis During Rituximab Therapy for Rheumatoid Arthritis: Data from the French AIR Registry

2012 ◽  
Vol 39 (5) ◽  
pp. 893-898 ◽  
Author(s):  
LAURE THOMAS ◽  
FLORENCE CANOUI-POITRINE ◽  
JACQUES-ERIC GOTTENBERG ◽  
ANDRA ECONOMU-DUBOSC ◽  
FATIHA MEDKOUR ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Incidence Rates ◽  
Causative Role ◽  
French Society ◽  
Additional Information ◽  
Set Up ◽  
Factor Α ◽  
Necrosis Factor ◽  
New Onset

Objective.Psoriasis could be a paradoxical reaction to tumor necrosis factor-α antagonist therapy and it has been reported with rituximab therapy. Our objective was to assess the rates of new-onset and flare of preexisting psoriasis in patients taking rituximab for rheumatoid arthritis (RA).Methods.The nationwide multicenter prospective AutoImmunity and Rituximab (AIR) registry was set up in 2006 by the French Society for Rheumatology to collect data on patients taking rituximab for joint diseases. We identified patients with RA in the registry who had psoriasis listed as an adverse drug reaction, and we obtained additional information from their physicians if needed. We computed the incidence rates of new-onset and flare of preexisting psoriasis according to the rituximab exposure time.Results.Among the 1927 patients in the registry with RA, 2 had new-onset and 5 had flare of preexisting psoriasis after a median followup of 39.2 weeks. Incidence rates were 1.04/1000 person-years (95% CI 0.13 to 3.8) for new-onset psoriasis and 2.6/1000 person-years (95% CI 0.84 to 6.1) for flare of preexisting psoriasis. Rituximab rechallenge in the 2 new-onset cases and in 2 flare cases was not followed by recurrence or exacerbation of psoriasis. Two of the 5 flare cases developed after discontinuation of methotrexate.Conclusion.Despite the small number of cases observed, leading to wide CI, the incidence rates in our study do not support a causative role of rituximab therapy in new-onset or flare of preexisting psoriasis in patients with RA.

scholarly journals Longterm, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-based Registry

2019 ◽  
Vol 47 (7) ◽  
pp. 959-967 ◽  
Author(s):  
Leslie R. Harrold ◽  
Jenny Griffith ◽  
Patrick Zueger ◽  
Heather J. Litman ◽  
Bernice Gershenson ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Median Time ◽  
Real World ◽  
Clinical Care ◽  
Incidence Rates ◽  
First Year ◽  
Serious Infection ◽  
Infection Event ◽  
Serious Infections ◽  
Using Data

Objective.To assess longterm safety in a US cohort of patients with rheumatoid arthritis (RA) treated with adalimumab (ADA) in real-world clinical care settings.Methods.This observational study analyzed the longterm incidence of safety outcomes among patients with RA initiating ADA, using data from the Corrona RA registry. Patients were adults (≥ 18 yrs) who initiated ADA treatment between January 2008 and June 2017, and who had at least 1 followup visit.Results.In total, 2798 ADA initiators were available for analysis, with a mean age of 54.5 years, 77% female, and mean disease duration of 8.3 years. Nearly half (48%) were biologic-naive, and 9% were using prednisone ≥ 10 mg at ADA initiation. The incidence rates per 100 person-years for serious infections, congestive heart failure requiring hospitalization, malignancy (excluding nonmelanoma skin cancer), and all-cause mortality were 1.86, 0.15, 0.64, and 0.33, respectively. The incidence of serious infections was higher in the first year of therapy (3.44, 95% CI 2.45–4.84) than in subsequent years, while other measured adverse effects did not vary substantially by duration of exposure. The median time to ADA discontinuation was 11 months, while the median time to first serious infection among those experiencing a serious infection event was 12 months.Conclusion.Analysis of longterm data from this prospective real-world registry demonstrated a safety profile consistent with previous studies in patients with RA. This analysis did not identify any new safety signals associated with ADA treatment and provides guidance for physicians prescribing ADA for extended periods.

scholarly journals Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register

2011 ◽  
Vol 70 (10) ◽  
pp. 1810-1814 ◽  
Author(s):  
J B Galloway ◽  
K L Hyrich ◽  
L K Mercer ◽  
W G Dixon ◽  
A P Ustianowski ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Septic Arthritis ◽  
Joint Infection ◽  
Incidence Rates ◽  
British Society ◽  
Joint Replacement Surgery ◽  
Replacement Surgery ◽  
Life Threatening ◽  
Using Data ◽  
Biologics Register

ObjectivesTo evaluate the risk of septic arthritis (SA) in patients with rheumatoid arthritis (RA) treated with anti-tumour necrosis factor (TNF) therapy.MethodsUsing data from the British Society for Rheumatology Biologics Register, a prospective observational study, the authors compared the risk of SA between 11 881 anti-TNF-treated and 3673 non-biological disease-modifying antirheumatic drug (nbDMARD)-treated patients.Results199 patients had at least one episode of SA (anti-TNF: 179, nbDMARD: 20). Incidence rates were: anti-TNF 4.2/1000 patient years (pyrs) follow-up (95% CI 3.6 to 4.8), nbDMARD 1.8/1000 pyrs (95% CI 1.1 to 2.7). The adjusted HR for SA in the anti-TNF cohort was 2.3 (95% CI 1.2 to 4.4). The risk did not differ significantly between the three agents: adalimumab, etanercept and infliximab. The risk was highest in the early months of therapy. The patterns of reported organisms differed in the anti-TNF cohort. Prior joint replacement surgery was a risk factor for SA in all patients. The rate of postoperative joint infection (within 90 days of surgery) was 0.7%. This risk was not significantly influenced by anti-TNF therapy.ConclusionsAnti-TNF therapy use in RA is associated with a doubling in the risk of SA. Physicians and surgeons assessing the RA patient should be aware of this potentially life-threatening complication.

The safety of anakinra in high-risk patients with active rheumatoid arthritis: Six-month observations of patients with comorbid conditions

2004 ◽  
Vol 50 (6) ◽  
pp. 1752-1760 ◽  
Author(s):  
Michael H. Schiff ◽  
Gino DiVittorio ◽  
John Tesser ◽  
Roy Fleischmann ◽  
Joy Schechtman ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
High Risk ◽  
Active Rheumatoid Arthritis ◽  
Comorbid Conditions ◽  
High Risk Patients ◽  
Risk Patients

Marked Reduction of Socioeconomic and Racial Disparities in Invasive Pneumococcal Disease Associated With Conjugate Pneumococcal Vaccines

2020 ◽  
Author(s):  
Rameela Raman ◽  
Julia Brennan ◽  
Danielle Ndi ◽  
Chantel Sloan ◽  
Tiffanie M Markus ◽  
...  
Keyword(s):  
Socioeconomic Factors ◽  
Racial Disparities ◽  
Invasive Pneumococcal Disease ◽  
Marked Reduction ◽  
Pneumococcal Disease ◽  
Disease Incidence ◽  
Incidence Rates ◽  
Individual Level ◽  
Level Data ◽  
Neighborhood Level

Abstract Background It is not known whether reductions in socioeconomic and racial disparities in incidence of invasive pneumococcal disease (defined as the isolation of Streptococcus pneumoniae from a normally sterile body site) noted after pneumococcal conjugate vaccine (PCV) introduction have been sustained. Methods Individual-level data collected from 20 Tennessee counties participating in Active Bacterial Core surveillance over 19 years were linked to neighborhood-level socioeconomic factors. Incidence rates were analyzed across 3 periods—pre–7-valent PCV (pre-PCV7; 1998–1999), pre–13-valent PCV (pre-PCV13; 2001–2009), and post-PCV13 (2011–2016)—by socioeconomic factors. Results A total of 8491 cases of invasive pneumococcal disease were identified. Incidence for invasive pneumococcal disease decreased from 22.9 (1998–1999) to 17.9 (2001–2009) to 12.7 (2011–2016) cases per 100 000 person-years. Post-PCV13 incidence (95% confidence interval [CI]) of PCV13-serotype disease in high- and low-poverty neighborhoods was 3.1 (2.7–3.5) and 1.4 (1.0–1.8), respectively, compared with pre-PCV7 incidence of 17.8 (15.7–19.9) and 6.4 (4.9–7.9). Before PCV introduction, incidence (95% CI) of PCV13-serotype disease was higher in blacks than whites (17.3 [15.1–19.5] vs 11.8 [10.6–13.0], respectively); after introduction, PCV13-type disease incidence was greatly reduced in both groups (white: 2.7 [2.4–3.0]; black: 2.2 [1.8–2.6]). Conclusions Introduction of PCV13 was associated with substantial reductions in overall incidence and socioeconomic and racial disparities in PCV13-serotype incidence.

Sign in / Sign up

Export Citation Format

Share Document